MENU
INAB
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

IN8bio (INAB) Ownership - Who owns IN8bio?

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells... Show more

Profile

Industry
N/A
Address
350 5th Avenue
Phone
+1 646 600-6438
Employees
31
Web
https://www.in8bio.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
329.77M
P/E Ratio
N/A
Total Cash
11.89M
Projected Growth
N/A
Total Debt
4.27M
Revenue
N/A
Risk (Beta)
0.11
Dividend Yield
N/A
Total Cash/Share
0.13
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

INAB
Capitalization
330M
P/E Ratio
N/A
Risk (Beta)
0.11
Dividend Yield
N/A
Total Cash
11.9M
Total Cash/Share
0.13
Total Debt
4.27M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
13.9M
P/B Ratio
23.75
Cash Flow
N/A
Earnings
-0.44
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
8K
Current Ratio
4.30
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-23.92M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-120.77
Shares Held By Institutions
7.51M
Shares Outstanding - Current
90.8M
Total Liabilities
5.99M
Total Volume MTD
N/A
Value
-1
Gain YTD
-52.916
View a ticker or compare two or three
INAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
350 5th Avenue
Phone
+1 646 600-6438
Employees
31
Web
https://www.in8bio.com